AbbVie to invest $380 million to expand US manufacturing in Illinois

AbbVie plans to invest $380 million to construct two new active pharmaceutical ingredient manufacturing facilities at its Illinois campus. This expansion will boost domestic production capacity for its neuroscience and obesity medicines, aligning with efforts to shore up U.S. manufacturing amid new tariffs on pharmaceutical imports. The new facilities, expected to be operational in 2029, will create 300 jobs and integrate advanced manufacturing technologies and AI.